Risk factors
Moleculin Biotech (MBRX) risk factors
Item 1A of every Moleculin Biotech, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors82 risks17 new9 dropped13 reworded
Moleculin faces intense dependency on single-source suppliers for drug candidates like Annamycin and requires continuous external funding to survive.
Filed Mar 18, 2026 - FY2024 10-K risk factors74 risks
Moleculin Biotech operates as a clinical-stage pharmaceutical company with no approved products, relying heavily on third-party manufacturers, physician-sponsored trials, and additional funding to advance its oncology pipeline.
Filed Mar 21, 2025